Interaction of Cbz-PEG with other substances

Cbz-PEG is a pharmaceutical intermediate. Cbz-PEG is a polymer with the chemical formula HO(CH2CH2O) nH, non-irritating, slightly bitter, with good water solubility and good compatibility with many organic components. Next is a description of the interactions between Cbz-PEG and other substances.

Here is the content list:

l Dose adjustment

l Other drug interactions

Dose adjustment

Bioavailability stable Cbz-PEG is a potent inducer of hepatic 3A4 and is also known to be an inducer of CYP1A2, 2B6, and 2C9/19, and therefore may reduce their metabolism by inducing plasma concentrations of combination drugs metabolized primarily by CYP 1A2, 2B6, 2C9/19, and 3A4. When used with Cbz-PEG, it may be necessary to monitor the concentrations of these drugs or adjust the dose. When Cbz-PEG is added to aripiprazole, the aripiprazole dose should be doubled. Additional dose increases should be based on clinical evaluation. If drugs made with Cbz-PEG are subsequently discontinued, the dose of aripiprazole should be reduced. When Cbz-PEG is used with tacrolimus, monitoring of tacrolimus blood levels and appropriate dose adjustment is recommended. Concomitant use of potent CYP3A4 inducers such as Cbz-PEG with tacrolimus should be avoided. if a patient must take both a drug made with organic chemistry hydrophilic Cbz-PEG and tacrolimus, dose adjustment of tacrolimus should be considered. The use of Cbz-PEG together with lapatinib should usually be avoided. If a patient already taking lapatinib is started on a drug made with Cbz-PEG, the dose of lapatinib should be gradually increased. If a drug made with Cbz-PEG is discontinued, the dose of lapatinib should be reduced. Concomitant use of drugs made with Cbz-PEG with nefazodone may result in insufficient plasma concentrations of nefazodone and its active metabolites to achieve a therapeutic effect. The combination of drugs made with Cbz-PEG with nefazodone is contraindicated. Monitor the concentration of valproate when introducing or discontinuing drugs made with Cbz-PEG in patients on valproate.

Other drug interactions

Cyclophosphamide is an inactive prodrug that is partially converted to its active metabolite via CYP3A. Prolonged co-administration of CYP3A4 inducers has been reported to increase the metabolic rate and leukopenic activity of cyclophosphamide. Toxicity of cyclophosphamide may be increased when co-administered with pharmaceuticals non-toxic 98% Cbz-PEG. Concomitant administration of drugs made with Cbz-PEG and lithium may increase the risk of neurotoxic side effects. The combination of drugs made with Cbz-PEG and isoniazid has been reported to increase isoniazid-induced hepatotoxicity. Alterations in thyroid function have been reported when combined with other anticonvulsant drugs. Concomitant use of drugs made with Cbz-PEG with hormonal contraceptive products may make the contraceptive less effective because plasma concentrations of the hormone may be reduced. Breakthrough bleeding and unintended pregnancies have been reported. A change or alternate method of contraception should be considered. Resistance to the neuromuscular blocking effects of the nondepolarizing neuromuscular blockers pancuronium bromide, vecuronium bromide, rocuronium bromide, and cis-atracurium has developed in patients who have been taking drugs made with Cbz-PEG for a long time. Whether drugs made with Cbz-PEG have the same effect on other nondepolarizing agents is not known. Patients should be monitored closely for faster than expected recovery from neuromuscular blockade, and the infusion rate requirements may be higher.

Chengdu Pukang Biotechnology Co., Ltd reminds you that Cbz-PEG is a very important pharmaceutical ingredient.